Global Central Nervous System Therapeutics Market, By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others), By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospital, Clinics, Diagnostic Laboratories, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region, Competition Forecast & Opportunities, 2026

August 2021 | 118 pages | ID: G96B503BECBCEN
TechSci Research

Abstracts

Global Central Nervous System Therapeutics market was valued USD 82947.46 million in 2020 and is forecast to grow with an impressive CAGR of 7.4% in the forecast period. The market showed a steady growth in the historical years and is expected to continue to grow in the next five years too. The growth of the market can be attributed to the increasing demand for the effective treatment plans and better medication. Furthermore, the rising foreign direct investments are also contributing to the growth of the global central nervous system therapeutics market.

Global Central Nervous System Therapeutics market is segmented by drug class, application, route of administration, end user, distribution channels, and regional distribution and by company. Based on drug class the market is further fragmented into multiple sclerosis, antipsychotic, antiepileptics, analgesics & anesthetics, anti-Parkinson, and others. The multiple sclerosis sub-segment is expected to dominate the market in the future whereas antiepileptics is expected to grow at a faster rate.

The application segment is further fragmented into neurodegenerative diseases, mental health and trauma, neurovascular diseases, infectious diseases, CNS cancer and others. The neurodegenerative diseases sub-segment is dominating the Central Nervous System Therapeutics Market accounting for 34.29% of total market share in 2020. Over the forecast period, the category is expected to maintain its dominance. The rising incidence of neurodegenerative disorders such as Multiple Sclerosis, Alzheimer's and Parkinson's, as well as the high cost of treatment of these neurodegenerative disorders, are expected to boost the segmental share.

According to the Parkinson’s Foundation, in United States alone, there were approximately 930,000 people suffering from Parkinson diseases in 2020 and it is estimated that by 2030, there will be around 1.2 million people in the United States with Parkinson disease. According to the National Council of Behavioral Health, approximately 70% of adults, in the United States will be exposed to some form of traumatic events once in their lifetime.

Future of the market is favorably dependent on the advancement of therapeutic drugs for central nervous system disorders. The market experiences a rising demand for effective drugs and motivating investments from pharmaceutical companies in research and development.

Some of the major players in the market are Biogen Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Novartis AG, Sanofi AG, Eli Lilly and Company Ltd., Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Bayer AG, Otsuka Holdings Co. Ltd., Amgen Inc., Bristol Myers Squibb Pharmaceuticals Ltd. among others. The companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.

Years considered for this report:

• Historical Years: 2016 – 2019
• Base Year: 2020
• Estimated Year: 2021
• Forecast Period: 2022 – 2026

Objective of the Study:

• To analyze the historical growth in the market size of Global central nervous system therapeutics market from 2016 to 2020.
• To estimate and forecast the market size of Global central nervous system therapeutics market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast Global central nervous system therapeutics market based on drug class, application, route of administration, end User, distribution channel, and regional distribution.
• To identify dominant region or segment in the Global central nervous system therapeutics market.
• To identify drivers and challenges for Global central nervous system therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global central nervous system therapeutics market.
• To identify and analyze the profile of leading players operating in Global central nervous system therapeutics market.
• To identify key sustainable strategies adopted by market players in Global central nervous system therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and distributors across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of Global central nervous system therapeutics market using a bottom-up approach, wherein data for various end-User segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Central nervous system therapeutics manufacturers, end user, distributors and other stakeholders
• distributors and suppliers of central nervous system therapeutic drugs and other stakeholders
• Organizations, forums, and alliances related to central nervous system therapeutics
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end User, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global central nervous system therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Global Central Nervous System Therapeutics Market, By Drug Class:
• Multiple Sclerosis
• Antipsychotic
• Antiepileptics
• Analgesics & Anesthetics
• Anti-Parkinson
• Others
• Global Central Nervous System Therapeutics Market, By Application:
• Neurodegenerative Diseases
• Mental Health and Trauma
• Neurovascular Diseases
• Infectious Diseases
• CNS Cancer
• Others
• Global Central Nervous System Therapeutics Market, By Route of Administration:
• Oral
• Parenteral
• Others
• Global Central Nervous System Therapeutics Market, By End User:
• Hospitals
• Clinics
• Diagnostic Laboratories
• Others
• Global Central Nervous System Therapeutics Market, By Distribution Channel:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Global Central Nervous System Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• APAC
• China
• Japan
• India
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• MEA
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global central nervous system therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET

4. EXECUTIVE SUMMARY

5. VOICE OF CUSTOMER

5.1. Factors Driving Global Central Nervous System Therapeutics Market
5.2. Factors Influencing Purchase Decision of Central Nervous System Drugs
5.3. Brand Awareness

6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
  6.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
  6.2.3. By Route of Administration (Oral, Parenteral, Others)
  6.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
  6.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  6.2.6. By Company (2020)
  6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
6.3. Market Map

7. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drug Class
  7.2.2. By Application
  7.2.3. By Route of Administration
  7.2.4. By End User
  7.2.5. By Distribution Channel
  7.2.6. By Country (United States; Canada; Mexico)
7.3. North America: Country Analysis
  7.3.1. United States Central Nervous System Therapeutics Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drug Class
      7.3.1.2.2. By Application
      7.3.1.2.3. By Route of Administration
      7.3.1.2.4. By End User
      7.3.1.2.5. By Distribution Channel
  7.3.2. Canada Central Nervous System Therapeutics Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drug Class
      7.3.2.2.2. By Application
      7.3.2.2.3. By Route of Administration
      7.3.2.2.4. By End User
      7.3.2.2.5. By Distribution Channel
  7.3.3. Mexico Central Nervous System Therapeutics Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drug Class
      7.3.3.2.2. By Application
      7.3.3.2.3. By Route of Administration
      7.3.3.2.4. By End User
      7.3.3.2.5. By Distribution Channel

8. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Class
  8.2.2. By Application
  8.2.3. By Route of Administration
  8.2.4. By End User
  8.2.5. By Distribution Channel
  8.2.6. By Country (Germany; France; United Kingdom; Italy; Spain)
8.3. Europe: Country Analysis
  8.3.1. Germany Central Nervous System Therapeutics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drug Class
      8.3.1.2.2. By Application
      8.3.1.2.3. By Route of Administration
      8.3.1.2.4. By End User
      8.3.1.2.5. By Distribution Channel
  8.3.2. France Central Nervous System Therapeutics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drug Class
      8.3.2.2.2. By Application
      8.3.2.2.3. By Route of Administration
      8.3.2.2.4. By End User
      8.3.2.2.5. By Distribution Channel
  8.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drug Class
      8.3.3.2.2. By Application
      8.3.3.2.3. By Route of Administration
      8.3.3.2.4. By End User
      8.3.3.2.5. By Distribution Channel
  8.3.4. Italy Central Nervous System Therapeutics Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Drug Class
      8.3.4.2.2. By Application
      8.3.4.2.3. By Route of Administration
      8.3.4.2.4. By End User
      8.3.4.2.5. By Distribution Channel
  8.3.5. Spain Central Nervous System Therapeutics Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Drug Class
      8.3.5.2.2. By Application
      8.3.5.2.3. By Route of Administration
      8.3.5.2.4. By End User
      8.3.5.2.5. By Distribution Channel

9. APAC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Class
  9.2.2. By Application
  9.2.3. By Route of Administration
  9.2.4. By End User
  9.2.5. By Distribution Channel
  9.2.6. By Country (China; Japan; India; South Korea; Australia)
9.3. APAC: Country Analysis
  9.3.1. China Central Nervous System Therapeutics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Class
      9.3.1.2.2. By Application
      9.3.1.2.3. By Route of Administration
      9.3.1.2.4. By End User
      9.3.1.2.5. By Distribution Channel
  9.3.2. Japan Central Nervous System Therapeutics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Class
      9.3.2.2.2. By Application
      9.3.2.2.3. By Route of Administration
      9.3.2.2.4. By End User
      9.3.2.2.5. By Distribution Channel
  9.3.3. India Central Nervous System Therapeutics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Class
      9.3.3.2.2. By Application
      9.3.3.2.3. By Route of Administration
      9.3.3.2.4. By End User
      9.3.3.2.5. By Distribution Channel
  9.3.4. South Korea Central Nervous System Therapeutics Market Outlook
    9.3.4.1. Market Size & Forecast
      9.3.4.1.1. By Value
    9.3.4.2. Market Share & Forecast
      9.3.4.2.1. By Drug Class
      9.3.4.2.2. By Application
      9.3.4.2.3. By Route of Administration
      9.3.4.2.4. By End User
      9.3.4.2.5. By Distribution Channel
  9.3.5. Australia Central Nervous System Therapeutics Market Outlook
    9.3.5.1. Market Size & Forecast
      9.3.5.1.1. By Value
    9.3.5.2. Market Share & Forecast
      9.3.5.2.1. By Drug Class
      9.3.5.2.2. By Application
      9.3.5.2.3. By Route of Administration
      9.3.5.2.4. By End User
      9.3.5.2.5. By Distribution Channel

10. SOUTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drug Class
  10.2.2. By Application
  10.2.3. By Route of Administration
  10.2.4. By End User
  10.2.5. By Distribution Channel
  10.2.6. By Country (Brazil; Argentina; Colombia)
10.3. South America: Country Analysis
  10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drug Class
      10.3.1.2.2. By Application
      10.3.1.2.3. By Route of Administration
      10.3.1.2.4. By End User
      10.3.1.2.5. By Distribution Channel
  10.3.2. Argentina Central Nervous System Therapeutics Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drug Class
      10.3.2.2.2. By Application
      10.3.2.2.3. By Route of Administration
      10.3.2.2.4. By End User
      10.3.2.2.5. By Distribution Channel
  10.3.3. Colombia Central Nervous System Therapeutics Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Type
      10.3.3.2.2. By Drug Class
      10.3.3.2.3. By Application
      10.3.3.2.4. By Route of Administration
      10.3.3.2.5. By End User
      10.3.3.2.6. By Distribution Channel

11. MEA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Drug Class
  11.2.2. By Application
  11.2.3. By Route of Administration
  11.2.4. By End User
  11.2.5. By Distribution Channel
  11.2.6. By Country (South Africa; Saudi Arabia; UAE)
11.3. MEA: Country Analysis
  11.3.1. South Africa Central Nervous System Therapeutics Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Drug Class
      11.3.1.2.2. By Application
      11.3.1.2.3. By Route of Administration
      11.3.1.2.4. By End User
      11.3.1.2.5. By Distribution Channel
  11.3.2. Saudi Arabia Central Nervous System Therapeutics Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Drug Class
      11.3.2.2.2. By Application
      11.3.2.2.3. By Route of Administration
      11.3.2.2.4. By End User
      11.3.2.2.5. By Distribution Channel
  11.3.3. UAE Central Nervous System Therapeutics Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Drug Class
      11.3.3.2.2. By Application
      11.3.3.2.3. By Route of Administration
      11.3.3.2.4. By End User
      11.3.3.2.5. By Distribution Channel

12. MARKET DYNAMICS

12.1. Drivers
12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

14. COMPETITIVE LANDSCAPE

14.1. Competition Outlook
14.2. Global Players Profiled (Leading Companies)
  14.2.1. Biogen Inc.
  14.2.2. Johnson & Johnson
  14.2.3. F. Hoffmann-La Roche AG
  14.2.4. Novartis AG
  14.2.5. Sanofi AG
  14.2.6. Eli Lilly and Company Ltd.
  14.2.7. Pfizer Inc.
  14.2.8. Merck & Co. Inc.
  14.2.9. AstraZeneca PLC
  14.2.10. Teva Pharmaceutical Industries Ltd.
  14.2.11. GlaxoSmithKline PLC
  14.2.12. Bayer AG
  14.2.13. Otsuka Holdings Co. Ltd.
  14.2.14. Amgen Inc.
  14.2.15. Bristol Myers Squibb Pharmaceuticals Ltd.

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

List Of Figures

LIST OF FIGURES

Figure 1: Global Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 2: Global Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 3: Global Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 4: Global Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 5: Global Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 6: Global Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 7: Global Central Nervous System Therapeutics Market Share, By Company, 2016-2026F
Figure 8: Global Central Nervous System Therapeutics Market Share, By Region, By Value, 2016-2026F
Figure 9: Global Central Nervous System Therapeutics Market Size, Market Map, By Value, 2016-2026F
Figure 10: North America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 11: North America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 12: North America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 13: North America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 14: North America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 15: North America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 16: North America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 17: United States Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 18: United States Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 19: United States Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 20: United States Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 21: United States Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 22: United States Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 23: Canada Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 24: Canada Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 25: Canada Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 26: Canada Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 27: Canada Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 28: Canada Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 29: Mexico Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 30: Mexico Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 31: Mexico Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 32: Mexico Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 33: Mexico Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 34: Mexico Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 35: Europe Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 36: Europe Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 37: Europe Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 38: Europe Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 39: Europe Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 40: Europe Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 41: Europe Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 42: Germany Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 43: Germany Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 44: Germany Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 45: Germany Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 46: Germany Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 47: Germany Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 48: France Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 49: France Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 50: France Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 51: France Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 52: France Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 53: France Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 54: United Kingdom Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 55: United Kingdom Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 56: United Kingdom Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 57: United Kingdom Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 58: United Kingdom Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 59: United Kingdom Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 60: Italy Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 61: Italy Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 62: Italy Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 63: Italy Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 64: Italy Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 65: Italy Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 66: Spain Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 67: Spain Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 68: Spain Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 69: Spain Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 70: Spain Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 71: Spain Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 72: APAC Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 73: APAC Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 74: APAC Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 75: APAC Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 76: APAC Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 77: APAC Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 78: APAC Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 79: China Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 80: China Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 81: China Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 82: China Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 83: China Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 84: China Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 85: Japan Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 86: Japan Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 87: Japan Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 88: Japan Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 89: Japan Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 90: Japan Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 91: India Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 92: India Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 93: India Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 94: India Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 95: India Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 96: India Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 97: South Korea Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 98: South Korea Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 99: South Korea Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 100: South Korea Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 101: South Korea Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 102: South Korea Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 103: Australia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 104: Australia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 105: Australia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 106: Australia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 107: Australia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 108: Australia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 109: South America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 110: South America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 111: South America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 112: South America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 113: South America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 114: South America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 115: South America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 116: Brazil Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 117: Brazil Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 118: Brazil Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 119: Brazil Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 120: Brazil Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 121: Brazil Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 122: Argentina Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 123: Argentina Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 124: Argentina Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 125: Argentina Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 126: Argentina Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 127: Argentina Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 128: Colombia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 129: Colombia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 130: Colombia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 131: Colombia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 132: Colombia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 133: Colombia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 134: MEA Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 135: MEA Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 136: MEA Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 137: MEA Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 138: MEA Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 139: MEA Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 140: MEA Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 141: South Africa Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 142: South Africa Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 143: South Africa Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 144: South Africa Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 145: South Africa Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 146: South Africa Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 147: Saudi Arabia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 148: Saudi Arabia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
Figure 149: Saudi Arabia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
Figure 150: Saudi Arabia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
Figure 151: Saudi Arabia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
Figure 152: